IL-10 release requires stronger toll-like receptor 4-triggering than TNF: A possible explanation for the selective effects of heterozygous TLR4 polymorphism Asp(299)Gly on IL-10 release

Immunobiology

Volumn 213, Issue 8, 2008, Pages 621-627

  Dehus, Oliver ^a   Bunk, Sebastian ^a   von Aulock, Sonja ^a   Hermann, Corinna ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Cytokine induction; Human monocytes; IL 10 release; LPS; TLR4 Asp(299)Gly polymorphism

Indexed keywords

ASPARTIC ACID; GLYCINE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ALLELE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FREQUENCY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; LEUKOCYTE; MELTING POINT; MONOCYTE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VOLUNTEER; WILD TYPE;

ALLELES; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50249121108     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2008.03.001     Document Type: Article

References (17)

1. Adib-Conquy M., Moine P., Asehnoune K., Edouard A., Espevik T., Miyake K., Werts C., and Cavaillon J.M. Toll-like receptor-mediated tumor necrosis factor and interleukin-10 production differ during systemic inflammation. Am. J. Respir. Crit. Care Med. 168 (2003) 158-164
2. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Frees K., Watt J.L., and Schwartz D.A. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25 (2000) 187-191
3. Calvano J.E., Bowers D.J., Coyle S.M., Macor M., Reddell M.T., Kumar A., Calvano S.E., and Lowry S.F. Response to systemic endotoxemia among humans bearing polymorphisms of the Toll-like receptor 4 (hTLR4). Clin. Immunol. 121 (2006) 186-190
4. Erridge C., Stewart J., and Poxton I.R. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J. Exp. Med. 197 (2003) 1787-1791
5. Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., Quertinmont E., Abramowicz M., Van Gossum A., Deviere J., and Rutgeerts P. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53 (2004) 987-992
6. Hacker H., Redecke V., Blagoev B., Kratchmarova I., Hsu L.C., Wang G.G., Kamps M.P., Raz E., Wagner H., Hacker G., Mann M., and Karin M. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439 (2006) 204-207
7. Heesen M., Wessiepe M., Kunz D., Vasickova K., and Blomeke B. Rapid and reliable genotyping for the Toll-like receptor 4 A896G polymorphism using fluorescence-labeled hybridization probes in a real-time polymerase chain reaction assay. Clin. Chim. Acta 333 (2003) 47-49
8. Hermann C. Variability of host-pathogen interaction. J. Endotoxin Res. 13 (2007) 199-218
9. Hoebe K., and Beutler B. LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif, Tram, and other TIR adaptor proteins. J. Endotoxin Res. 10 (2004) 130-136
10. Kuhn R., Lohler J., Rennick D., Rajewsky K., and Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
11. Latz E., Visintin A., Lien E., Fitzgerald K.A., Monks B.G., Kurt-Jones E.A., Golenbock D.T., and Espevik T. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277 (2002) 47834-47843
12. Ma W., Lim W., Gee K., Aucoin S., Nandan D., Kozlowski M., Diaz-Mitoma F., and Kumar A. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J. Biol. Chem. 276 (2001) 13664-13674
13. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001) 683-765
14. Rallabhandi P., Bell J., Boukhvalova M.S., Medvedev A., Lorenz E., Arditi M., Hemming V.G., Blanco J.C., Segal D.M., and Vogel S.N. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J. Immunol. 177 (2006) 322-332
15. Schippers E.F., van 't Veer C., van Voorden S., Martina C.A., le Cessie S., and van Dissel J.T. TNF-alpha promoter, Nod2 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine 26 (2004) 16-24
16. von Aulock S., Schroder N.W., Gueinzius K., Traub S., Hoffmann S., Graf K., Dimmeler S., Hartung T., Schumann R.R., and Hermann C. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J. Infect. Dis. 188 (2003) 938-943
17. Williams J.A., Pontzer C.H., and Shacter E. Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase. J. Interferon Cytokine Res. 20 (2000) 291-298